Adult Dosing
Treatment of HIV Infection (usually in combination with other antiretrovirals in treatment experienced patients with NNRTI resistance)
- 200 mg PO bid after meals
Pediatric Dosing
- Safety and effectiveness have not been established in pediatric patients <6 years of age
Treatment of HIV Infection (usually in combination with other antiretrovirals in treatment experienced patients with NNRTI resistance)
- 6 -
18 years 
16 kg to <20 kg: 100 mg PO bid- 20 kg to <25 kg: 125 mg PO bid
- 25 kg to <30 kg: 150 mg PO bid
- 30 kg: 200 mg PO bid
[Outline]
See Supplemental Patient Information
- Note: Etravirine is currently unlicensed in the UK but is available through an expanded access program and to patients on in certain clinical trials. In Australia it is under regulatory review
- Severe, potentially life threatening and fatal skin reactions including Stevens-Johnson syndrome, hypersensitivity reaction, toxic epidermal necrolysis and erythema multiforme have been reported
- Discontinue treatment if severe hypersensitivity, severe rash or liver transaminase elevations occur; monitor clinical status, including liver transaminases closely
- Opportunistic infections, inflammatory response may occur and require evaluation and treatment
- Autoimmune disorders including Graves disease, polymyositis, and Guillain-Barré syndrome may occur in the setting of immune reconstitution
Do not administer with:
- carbamazepine
- phenobarbital
- rifampin
- rifapentine
- St. Johns Wort
- rifabutin
- ritonavir
- protease inhibitors administered without ritonavir
- non-nucleoside reverse transcriptase inhibitors
Cautions: Use cautiously in
- Severe hepatic impairment
- Co-infection with hepatitis B or C virus
- Elderly patient
Supplemental Patient Information
- Instruct patients to discontinue etravirine and seek medical attention if severe hypersensitivity, severe rash or liver transaminase elevations occurred
- Inform Patients that redistribution or accumulation of body fat may occur receiving antiretroviral therapy
- Patients should be informed that etravirine does not cure HIV infection; may get opportunistic infections and other complications associated with HIV disease
- Patients should be informed that etravirine does not reduce the risk of passing HIV to others through sexual contact, sharing needles, or being exposed to blood
Pregnancy Category:B
Breastfeeding: Unsafe, Women with HIV infection should not breastfeed to avoid risking postnatal transmission of HIV.
Pricing data from www.DrugStore.com in U.S.A.
- Intelence 200 MG TABS [Bottle] (JANSSEN PRODUCTS)
60 mg = $871.03
180 mg = $2567.01 - Intelence 100 MG TABS [Bottle] (JANSSEN PRODUCTS)
120 mg = $876
360 mg = $2519
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Intelence 100 MG Oral Tablet
Ingredient(s): Etravirine
Imprint: TMC125;100
Color(s): White
Shape: Oval
Size (mm): 19.00
Score: 1
Inactive Ingredient(s): silicon dioxide / croscarmellose sodium / hypromellose / lactose monohydrate / magnesium stearate / cellulose, microcrystalline
Drug Label Author:
CENTOCOR ORTHO BIOTECH PRODUCTS, L.P.
DEA Schedule:
Non-Scheduled
